Clinical Trial

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The goal of this clinical research study is to find out if treatment with a combination of dasatinib plus ropeginterferon can help to control CML-CP. The safety of this combination will also be studied.
Protocol Amendment History 1 change
critical Recruitment opened 2026-08-08
Trial Details
NCT Number NCT07269470
Lead Sponsor M.D. Anderson Cancer Center
Conditions Chronic Myeloid Leukemia
Enrollment 40 participants
Start Date 2026-07-13
Primary Completion 2029-11-01 (estimated)
Study Completion 2029-11-01 (estimated)
Updated on ClinicalTrials.gov 2026-08-07